Zebra is a privately held pre-clinical stage biopharmaceutical company. The Company is pioneering the development of platform technologies that allow cellular function-based screening for the discovery and selection of fully human therapeutic biologics (antibodies, peptides or proteins) from DNA-encoded combinatorial libraries of human antibodies, peptides or “protein-in-proteins”. While applicable for lead discovery across all therapeutic areas and all receptor classes, Zebra has optimized the platform for the highly desirable feature of allowing selection of rare agonist antibodies from very large (>1011) combinatorial libraries.
Zebra holds exclusive licenses from the The Scripps Research Institute, San Diego to both the core platform technology and to current and future candidate therapeutics derived from the platform. Multiple proof of concept examples of the power of Zebra’s platform have been published from the laboratory of Dr. Richard A. Lerner, a Zebra co-founder and Professor at Scripps. Zebra is advancing an internal portfolio of novel full human agonist antibodies and novel highly selective ion-channel blockers.
Founded by an experienced team of academic scientists,
serial entrepreneurs and seasoned biopharma executives
Exclusive License to a Next Gen Combinatorial Antibody and
Peptide Library Technology Developed at the Scripps Res Inst.
Multi Year Sponsored Research Agreement with Scripps Res Inst.
Technology Allows a New a Approach to the Direct Discovery of
AGONIST and ANTAGONIST therapeutic biologic candidates in
FUNCTION-BASED screens with human receptor target cells
Seeking R&D collaborations across multiple disease areas with
global bio-pharma partners
Initial Discovery activities in San Diego and Shanghai -
collaboration with the Shanghai Inst for Advanced
Immunochemical Studies (SIAIS)
Future Preclinical R&D site in Boston